Page 1227 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

2 References

Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome 53. Dushay KM, Zibrak JD, Jensen WA. Myasthenia gravis present-
Trial Group. Lancet. 1997;349:225. ing as isolated respiratory failure. Chest. 1990;97:232.
33. Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor 54. Putman MT, Wise RA. Myasthenia gravis and upper airway
prognosis in Guillain Barre Syndrome. Neurology. 2011;76:968. obstruction. Chest. 1996;109:400.
34. Fletcher DD, Lawn ND, Wolter TD, et al. Long-term outcome 55. Berrouschot J, Baumann I, Kalischewskip P, et al. Therapy of
in patients with Guillain-Barré syndrome requiring mechanical myasthenic crisis. Crit Care Med. 1997;25:1228.
ventilation. Neurology. 2000;54:2311. 56. Thomas CE, Mayer SA, Gungor Y, et al. Myasthenic crisis:
35. Henderson RD, Lawn ND, Fletcher DD, et al. The morbidity of clinical features, mortality, complications, and risk factors for
Guillain-Barré syndrome admitted to the intensive care unit. prolonged intubation. Neurology. 1997;48:1253.
Neurology. 2003;60:17. 57. Mayer SA. Intensive care of the myasthenic patient. Neurology.
36. Elovaara I, Apostolski S, VanDoorn P, et al. EFNS guidelines for 1997;48(suppl 5):S70.
the use of intravenous immogulobulin in treatment of neuro- 58. Wittbrodt ET. Drugs and myasthenia gravis, an update. Arch
logical diseases. Eur J Neurol. 2008;15:893. Intern Med. 1997;157:399.
37. Hughes RAC, Swan AV, Raphael JC, et al. Immunotherapy 59. Perrot X, Bernard N, Vial C, et al. Myasthenia gravis exacerba-
for Guillain-Barre syndrome: a systematic review. Brain. tion or unmasking associated with telithromycin treatment.
2007;130:2245. Neurology. 2006;67:2256.
38. Plasmapheresis and acute Guillain-Barré syndrome. The 60. Seneviratne J, Mandrekar J, Wijdicks S, et al. Predictors of extu-
Guillain-Barré syndrome Study Group. Neurology. 1985;35:1096. bation failure in myasthenia gravis and myasthenia crises. Arch
Neurol. 2008;65:929.
39. Osterman PO, Fagius J, Lundemo G, et al. Beneficial effects of
plasma exchange in acute inflammatory polyradiculoneuropathy. 61. Golnik KC, Pena R, Lee AG, et al. An ice test for the diagnosis
Lancet. 1984;2:1296. of myarthenia gravis. Ophthalmology. 1999;106:1282.
40. Efficiency of plasma exchange in Guillain-Barré syndrome: a 62. Vernino S, Lennon VA. Autoantibody profiles and neurological
role of replacement fluids. French Cooperative Group on Plasma correlations of thymona. Clin Cancer Res. 2004;10:7270.
Exchange in Guillain-Barré syndrome. Ann Neurol. 1987;22:753. 63. Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment
41. Raphael JC, Chevret S, Auriant I, et al. Treatment of adult of autoimmune neuromuscular transmission disorders. Eur J
Guillain-Barré syndrome: indications for plasma exchange. Neurol. 2010;17:893.
Transfusion Sci. 1999;20:53. 64. Gajdos P, Chevret S, Clair B, et al. Clinical trial of plasma
exchange and high-dose intravenous immunoglobulin in myas-
42. Bouget J, Chevret S, Chastang C, et al. Plasma exchange mor-
bidity in Guillain-Barré syndrome: results from the French thenia gravis. Ann Neurol. 1997;41:789.
prospective, double-blind, randomized, multicenter study. Crit 65. Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange
Care Med. 1993;21:651. versus intravenous immunoglobulin treatment in myasthenic
crisis. Neurology. 1999;52:629.
43. van der Merché FGA, Schmitz PIM A randomized trial com-
paring intravenous immune globulin and plasma exchange in 66. Barth D, Nabavi NM, Ng E, et al. Comparison of IVIG and PLEX
Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. in patients with myasthenia gravis. Neurology. 2011;76:207.
N Engl J Med. 1992;326:1123. 67. Juel VC. Myasthenia gravis: management of myasthenia crises
44. Gelfand EW. Intravenous immune globulin in autoimmune and and preoperative care. Semin Neurol. 2004;24:75.
inflammatory diseases. N Eng J Med. 2012;367:2015. 68. Drachman DB, Jones RJ, Brodsky RA, et al. Treatment of refrac-
tory myasthenia: “Rebooting” with high-dose cyclophospha-
45. Buchwald B, Ahangari R, Weishaupt A, et al. Intravenous
immunoglobulins neutralize blocking antibodies in Guillain- mide. Ann Neurol. 2003;53:29.
Barré syndrome. Ann Neurol. 2002;51:673. 69. Gladstone D, Brannagan T, Schwartzman R, et al. High dose
cyclophosphamide for severe refractory myasthenia gravis.
46. Yuki N, Ang CW, Koga M, et al. Clinical features and response J Neurol Neurosurg Psychiatry. 2004;75(5):789.
to treatment in Guillain-Barré syndrome associated with anti-
bodies to GM ganglioside. Ann Neurol. 2000;47:314. 70. Diaz-Manera J, Martinez-Hernandez E, Querol L, et al. Long-
1b lasting treatment effect of rituximab in MusK myasthenia.
47. Drachman DB. Myasthenia gravis. N Engl J Med. 1994;330:1797. Neurology. 2012;78(3):189.
48. Alshekhlee A, Miles JD, Katirji B, et al. Incidence and mortality 71. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis.
rates of myasthenia gravis and myasthenic crises in U.S. hospitals. Lancet. 2003;362:971.
Neurology. 2009;72:1548.
72. Troyanov Y, Targoff IN, Tremblay JL, et al. Novel clarifica-
49. Lennon VA. Serologic profile of myasthenia gravis and distinc- tion of idiopathic inflammatory myopathies based on overlap
tion from the Lambert-Eaton myasthenic syndrome. Neurology. syndrome features and auto antibodies: analysis of 100 French
1997;48(suppl 5):S23. Canadian patients. Medicine. 2005;84:231.
50. Deymeer F, Gangor-Tuncor O, Yilmaz V, et al. Clinical com- 73. Tomasova Studynkova J, Charvat F, Jarosova K, et al. The role of
parison of anti-musk vs. anti-ACHR-positive and seronegative MRI in the assessment of polymyositis and dermatomyoositis.
myasthenia gravis. Neurology. 2007;68:609. Rheumatology. 2007;46(7):1174.
51. Pasnoor M, Wolfe GI, Nations S, et al. Clinical findings in 74. Schwartz MI. The lung in polymyositis. Clin Chest Med.
musk-antibody positive myasthenia gravis: a U.S. experience. 1998;19:701.
Muscle Nerve. 2010;41:370. 75. Haupt HM, Hutchins GM. The heart and cardiac conduction
52. Zulueta JJ, Fanburg BL. Respiratory dysfunction in myasthenia system in polymyositis-dermatomyositis: a clinicopathologic
gravis. Clin Chest Med. 1994;15:683. study of 16 autopsied patients. Am J Cardiol. 1982;50:998.

Section06-O-ref.indd 2 12/10/2014 6:03:41 PM